Blue Trust Inc. Decreases Stake in Insmed, Inc. $INSM

Blue Trust Inc. lowered its position in Insmed, Inc. (NASDAQ:INSM) by 37.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 564 shares of the biopharmaceutical company’s stock after selling 342 shares during the quarter. Blue Trust Inc.’s holdings in Insmed were worth $57,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. increased its holdings in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 221 shares during the last quarter. ORG Partners LLC increased its holdings in Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 196 shares during the last quarter. Hilltop National Bank purchased a new stake in Insmed in the 2nd quarter worth about $28,000. Signaturefd LLC increased its holdings in Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 325 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 386 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on INSM shares. JPMorgan Chase & Co. lifted their price objective on Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, August 20th. Evercore ISI reissued an “outperform” rating and issued a $180.00 price objective on shares of Insmed in a report on Wednesday, October 1st. The Goldman Sachs Group lifted their price objective on Insmed from $121.00 to $196.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Jefferies Financial Group lifted their target price on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. Finally, Truist Financial lifted their target price on Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $152.88.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the completion of the sale, the insider owned 36,461 shares in the company, valued at $5,303,252.45. The trade was a 67.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director owned 262,675 shares of the company’s stock, valued at $38,190,318.25. The trade was a 3.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 211,057 shares of company stock valued at $27,438,126 in the last ninety days. Insiders own 3.00% of the company’s stock.

Insmed Stock Up 1.6%

Shares of NASDAQ INSM opened at $165.76 on Friday. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $166.44. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $35.04 billion, a price-to-earnings ratio of -29.03 and a beta of 1.03. The business has a 50-day moving average of $143.38 and a 200-day moving average of $105.05.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analysts’ expectations of $104.06 million. During the same period in the previous year, the firm posted ($1.94) EPS. The firm’s revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.